B. Naser-Hijazi

Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high‐field 19F‐NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols

W. Hull, M. Berger, N. Lutz, 2004, NMR in biomedicine.

Locoregional administration of 5-fluoro-2′-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by19F-NMR spectroscopy

P. Schlag, W. Hull, M. Berger, 2005, Journal of Cancer Research and Clinical Oncology.

The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study.

C. Diehm, H. Partsch, E. Rabe, 2002, VASA. Zeitschrift fur Gefasskrankheiten.

Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo-controlled, double-blind study.

A. Bockisch, R. Kohnen, G. Belz, 2001, The British journal of oral & maxillofacial surgery.

Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin.

J. Freudenstein, M. Burian, H. Henneicke-von Zepelin, 2003, International journal of clinical pharmacology and therapeutics.

Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study.

E. Becker, H. Henneicke-von Zepelin, J. Schnitker, 2003, International journal of clinical pharmacology and therapeutics.

Evaluation of the safety of a coumarin–troxerutin combination

R. Bruppacher, P. Wüstenberg, B. Naser-Hijazi, 1998, Pharmacoepidemiology and drug safety.